GeneDx (WGS) - 2024 Q3 - Quarterly Results

Exhibit 99.1 GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights 1 Achieved profitability milestone with third quarter adjusted net income of $1.2M Reported third quarter 2024 revenues of $76.6M with 77% year-over-year growth of exome and genome test revenue 2 Expanded third quarter 2024 adjusted gross margins to 64% 2 Raising guidance to deliver between $284M and $290M in FY 2024 revenue GeneDx to host conference call today at 8:30 a.m. ET STAMFORD, Conn., October 29, 2024 — GeneDx ...